NASDAQ:NPCE NeuroPace (NPCE) Stock Price, News & Analysis $6.99 -0.44 (-5.92%) (As of 02:38 PM ET) Add Compare Share Share Today's Range$6.88▼$7.4950-Day Range$6.65▼$8.4652-Week Range$5.75▼$18.15Volume21,187 shsAverage Volume101,674 shsMarket Capitalization$201.09 millionP/E RatioN/ADividend YieldN/APrice Target$14.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get NeuroPace alerts: Email Address NeuroPace MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.86 Rating ScoreUpside/Downside95.3% Upside$14.00 Price TargetShort InterestBearish3.65% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.96Based on 3 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.08) to ($0.99) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.64 out of 5 starsMedical Sector443rd out of 927 stocksSurgical & Medical Instruments Industry53rd out of 101 stocks 3.4 Analyst's Opinion Consensus RatingNeuroPace has received a consensus rating of Moderate Buy. The company's average rating score is 2.86, and is based on 6 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageNeuroPace has only been the subject of 3 research reports in the past 90 days.Read more about NeuroPace's stock forecast and price target. Previous Next 2.0 Short Interest Percentage of Shares Shorted3.65% of the float of NeuroPace has been sold short.Short Interest Ratio / Days to CoverNeuroPace has a short interest ratio ("days to cover") of 5.4.Change versus previous monthShort interest in NeuroPace has recently increased by 6.04%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldNeuroPace does not currently pay a dividend.Dividend GrowthNeuroPace does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for NPCE. Previous Next 2.8 News and Social Media Coverage News SentimentNeuroPace has a news sentiment score of 0.96. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.68 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for NeuroPace this week, compared to 2 articles on an average week. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, NeuroPace insiders have not sold or bought any company stock.Percentage Held by Insiders22.20% of the stock of NeuroPace is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions78.83% of the stock of NeuroPace is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about NeuroPace's insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for NeuroPace are expected to grow in the coming year, from ($1.08) to ($0.99) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of NeuroPace is -6.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of NeuroPace is -6.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioNeuroPace has a P/B Ratio of 9.08. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about NeuroPace's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad DarwinCurious About AI's Next Big Winners? 🚀Wondering which AI stocks are set to soar in 2024? We’ve identified the top 3, and we're excited to share them with you! Unlock immediate access to our exclusive report and discover... the key players and strategic insights. Click below to opt-in and receive up to two additional free bonus subscriptions. Unsubscribe at any time.[Download Your Free Report Now] About NeuroPace Stock (NASDAQ:NPCE)NeuroPace, Inc. operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating medically refractory focal epilepsy. It also records continuous brain activity data and enables clinicians to monitor patients in person and remotely. Its RNS System includes RNS neurostimulator, cortical strip and depth leads, and Patient Remote Monitor, as well as other implantable and non-implantable accessories. The company sells its products to hospital facilities for initial RNS system implant procedures and for replacement procedures. NeuroPace, Inc. was incorporated in 1997 and is headquartered in Mountain View, California.Read More NPCE Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart NPCE Stock News HeadlinesSeptember 14 at 2:05 AM | americanbankingnews.comNeuroPace, Inc. (NASDAQ:NPCE) Receives $14.00 Average Target Price from AnalystsSeptember 5, 2024 | markets.businessinsider.comNeuroPace (NPCE) Gets a Buy from Lake StreetSeptember 16, 2024 | DTI (Ad)Weird phenomenon on AMZN stockWhat would you do if you knew that you could have bought Amazon on May 25th every year and walked away with a win?September 4, 2024 | globenewswire.comNeuroPace Strengthens Management Team with Two Key AppointmentsAugust 27, 2024 | globenewswire.comNeuroPace Announces Participation at Two Upcoming Healthcare Investor ConferencesAugust 22, 2024 | globenewswire.comNeuroPace to Participate in Upcoming Healthcare Conferences in SeptemberAugust 20, 2024 | seekingalpha.comNeuroPace: Only For Those With Strong NervesAugust 16, 2024 | markets.businessinsider.comNeuroPace: Strong Q2 Performance and Promising Future Drive ‘Outperform’ RatingSeptember 16, 2024 | DTI (Ad)Weird phenomenon on AMZN stockWhat would you do if you knew that you could have bought Amazon on May 25th every year and walked away with a win?August 16, 2024 | finance.yahoo.comEarnings Release: Here's Why Analysts Cut Their NeuroPace, Inc. (NASDAQ:NPCE) Price Target To US$14.57August 15, 2024 | finanznachrichten.deNeuroPace, Inc.: NeuroPace Reports Second Quarter 2024 Financial Results and Increases 2024 Revenue GuidanceAugust 14, 2024 | finance.yahoo.comNeuroPace Reports Second Quarter 2024 Financial Results and Increases 2024 Revenue GuidanceAugust 13, 2024 | markets.businessinsider.comNeuroPace earnings: here's what Wall Street expectsJuly 23, 2024 | globenewswire.comNeuroPace to Report Second Quarter 2024 Financial Results on August 13, 2024May 29, 2024 | markets.businessinsider.comStrong Sales Growth and Strategic Initiatives Justify Buy Rating for NeuroPaceMay 27, 2024 | finance.yahoo.comNeuroPace, Inc.'s (NASDAQ:NPCE) top owners are private equity firms with 47% stake, while 24% is held by institutionsMay 14, 2024 | finance.yahoo.comNeuroPace to Participate in Two Healthcare Conferences in MayMay 13, 2024 | finance.yahoo.comNeuroPace, Inc. (NASDAQ:NPCE) Q1 2024 Earnings Call TranscriptSee More Headlines Receive NPCE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for NeuroPace and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/13/2024Today9/16/2024Next Earnings (Estimated)11/04/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Surgical & medical instruments Sub-IndustryMedical Equipment Current SymbolNASDAQ:NPCE CUSIPN/A CIK1528287 Webwww.neuropace.com Phone650-237-2700FaxN/AEmployees170Year FoundedN/APrice Target and Rating Average Stock Price Target$14.00 High Stock Price Target$22.00 Low Stock Price Target$8.00 Potential Upside/Downside+88.4%Consensus RatingModerate Buy Rating Score (0-4)2.86 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)($1.19) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-32,960,000.00 Net Margins-41.63% Pretax Margin-41.63% Return on Equity-195.26% Return on Assets-29.88% Debt Debt-to-Equity Ratio5.97 Current Ratio6.37 Quick Ratio5.47 Sales & Book Value Annual Sales$71.82 million Price / Sales2.98 Cash FlowN/A Price / Cash FlowN/A Book Value$0.79 per share Price / Book9.41Miscellaneous Outstanding Shares28,768,000Free Float22,382,000Market Cap$213.75 million OptionableOptionable Beta1.80 20 High-Yield Dividend Stocks that Could Ruin Your RetirementAlmost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.Get This Free Report Key ExecutivesMr. Joel D. Becker (Age 56)CEO, President & Director Comp: $762kMs. Rebecca L. Kuhn (Age 63)CFO, VP of Finance & Administration, Corporate Secretary and Assistant Secretary Comp: $614.91kDr. Martha J. Morrell (Age 67)Chief Medical Officer Comp: $728.68kMs. Leah AkinActing General CounselMs. Kelley NicholasVice President of SalesMs. Irene Thomas (Age 55)Vice President of Human Resources More ExecutivesKey CompetitorsUtah Medical ProductsNASDAQ:UTMDTELA BioNASDAQ:TELABeyond AirNASDAQ:XAIRPAVmedNASDAQ:PAVMNational VisionNASDAQ:EYEView All CompetitorsInsiders & InstitutionsNantahala Capital Management LLCSold 161,437 shares on 8/20/2024Ownership: 2.144%Millennium Management LLCBought 80,324 shares on 8/15/2024Ownership: 2.385%Marshall Wace LLPSold 26,313 shares on 8/14/2024Ownership: 0.111%Cubist Systematic Strategies LLCSold 39,206 shares on 8/14/2024Ownership: 0.040%XTX Topco LtdBought 8,643 shares on 8/12/2024Ownership: 0.084%View All Insider TransactionsView All Institutional Transactions NPCE Stock Analysis - Frequently Asked Questions How have NPCE shares performed this year? NeuroPace's stock was trading at $10.31 at the beginning of the year. Since then, NPCE shares have decreased by 30.5% and is now trading at $7.17. View the best growth stocks for 2024 here. How were NeuroPace's earnings last quarter? NeuroPace, Inc. (NASDAQ:NPCE) announced its quarterly earnings results on Tuesday, August, 13th. The company reported ($0.26) EPS for the quarter, beating the consensus estimate of ($0.29) by $0.03. NeuroPace's revenue for the quarter was up 16.6% on a year-over-year basis. When did NeuroPace IPO? NeuroPace (NPCE) raised $85 million in an IPO on Thursday, April 22nd 2021. The company issued 5,300,000 shares at $15.00-$17.00 per share. J.P. Morgan and Morgan Stanley acted as the underwriters for the IPO and Wells Fargo and SVB Leerink were co-managers. Who are NeuroPace's major shareholders? NeuroPace's top institutional investors include Millennium Management LLC (2.38%), Nantahala Capital Management LLC (2.14%), Renaissance Technologies LLC (0.28%) and Acadian Asset Management LLC (0.24%). Insiders that own company stock include Ltd Kck, Accelmed Partners Ii LP, Orbimed Advisors Llc, Martha Morrell and Irina Ridley. View institutional ownership trends. How do I buy shares of NeuroPace? Shares of NPCE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:NPCE) was last updated on 9/16/2024 by MarketBeat.com Staff From Our PartnersMore Than 30 Federal Agencies Buy From This Cybersecurity TechIn January of 2022 Ukraine was hit by an especially nasty piece of malware, named WhisperGate. By then Ukra...Capital Trends | SponsoredBiden's Executive Order, Dems Digital Money Legislation, First Step ToDonald Trump once again sounded the alarm against Fed-controlled digital currencies (CBDCs). If these plans...Monetary Gold | Sponsored44-year Wall Street Vet: “Permanent devastation is coming to America”After 44 years on Wall Street, I've seen it all... Black Monday, the Great Recession, the Covid crash. B...InvestorPlace | SponsoredBREAKING NEWS: AI Tech Now Used to Stop School ShootersTwo seconds. That's all it takes for Knightscope's Automated Gunshot Detection to notify authorities and map a...Market JAR | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredPrepare for a Recession Unlike Any OtherDave Ramsey Is Dangerously Wrong And Here’s Why>> Asked whether we’re on the cusp of a US Dollar crash, Dav...American Hartford Gold Group | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredNvidia needs these 3 companies on a new $1 trillion SuperprojectNvidia is pivoting to a new $1 trillion Superproject that could revolutionize the AI industry… again. And i...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NeuroPace, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share NeuroPace With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
